Puma Biotechnology (PBYI) Asset Writedowns and Impairment (2020 - 2025)

Puma Biotechnology (PBYI) has 4 years of Asset Writedowns and Impairment data on file, last reported at $400000.0 in Q4 2025.

• Quarterly Asset Writedowns and Impairment rose 205.54% year-over-year to $400000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $213000.0 (up 136.79% YoY) and the FY2024 annual result came in at -$500000.0, down 156.75% from the prior year.
• Asset Writedowns and Impairment climbed to $400000.0 in Q4 2025, from -$100000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $514000.0 in Q2 2023 to a low of -$379000.0 in Q4 2024.
• A 3-year average of $51500.0 and a median of $0.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment plunged 203.27% — and 2025, when it jumped 205.54%.
• Tracing PBYI's Asset Writedowns and Impairment over 3 years: stood at $367000.0 in 2023, then sank by 203.27% to -$379000.0 in 2024, then jumped by 205.54% to $400000.0 in 2025.
• The last three Asset Writedowns and Impairment figures came in at $400000.0 (Q4 2025), -$100000.0 (Q3 2025), and -$300000.0 (Q2 2025), per Business Quant data.